Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults.
Level 2 - randomized trial
Randomized, double-blind, placebo-controlled crossover clinical trial.
PubMed 29599478 · doi:10.1038/s41467-018-03421-7
What was done
A 2 × 6-week randomized, double-blind, placebo-controlled crossover clinical trial evaluating chronic supplementation with the NAD+ precursor nicotinamide riboside (NR) in healthy middle-aged and older adults.
What was found
The abstract reports that chronic NR supplementation was well tolerated and effectively stimulated NAD+ metabolism. No specific quantitative measurements, baseline values, effect sizes, or p-values are reported in the abstract. The authors observed preliminary physiological effects and suggested future trials assess potential benefits for reducing blood pressure and arterial stiffness.
Why it matters
Provides human clinical trial evidence that oral nicotinamide riboside can safely increase NAD+ metabolism in healthy middle-aged and older individuals, supporting further research into its cardiovascular effects.
Limits
The abstract does not disclose the sample size, dosage, participant baseline characteristics, or numeric results with variance measures. Findings regarding blood pressure and arterial stiffness are preliminary suggestions rather than fully reported primary clinical endpoints.
Cited by
- supports A clinical trial led by Doug Seals administering 1,000 mg of nicotinamide riboside daily raised blood NAD levels but did not produce statistically significant improvements in physiological vascular endpoints.